ARTICLE SUMMARY:
Newtopia is in the business of disease prevention, which is generally not easy to demonstrate nor is the pathway to reimbursement straightforward. But with a performance-based revenue model that aligns the clinical and business objectives of all parties, Newtopia is having early success on several fronts for its digital platform: good outcomes for its participants, cost savings for its several large corporate and payor customers, and milestone-based revenues flowing in.
In early May, just as investors were feeling the full weight of the coronavirus pandemic, Toronto, Ontario-based Newtopia Inc. went public on Toronto’s TSX venture exchange (and as of August 6, had a market cap of about CDN $ 55.9 million).
Newtopia’s story does indeed have a pandemic angle, but not the usual one focused around respiratory tests and therapies. It’s in the business of providing a digital health-enabled disease prevention platform specifically designed for addressing (and reversing) known risk factors in patients headed for chronic diseases like diabetes, hypertension, and heart disease.